A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic Malignancies. - Dawson MA; Borthakur G; Huntly BJP; Karadimitris A; Alegre A; Chaidos A; Vogl DT; Pollyea DA; Davies FE; Morgan GJ; Glass JL; Kamdar M; et al. (Clinical cancer research : an official journal of the American Association for Cancer Research, 2023)